Baltimore, MD – According to filings with the U.S. Securities and Exchange Commission, Vita Therapeutics is raising $30,892,998.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Douglas Falk played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Vita Therapeutics
Vita Therapeutics is a cell engineering company harnessing the power of genetics to develop cellular therapies. Induced Pluripotent stem cells (iPSCs) are derived from somatic cells by temporary expression of four transcription factors, also referred to as the Yamanaka Factors. iPSCs share all the characteristics of embryonic stem cells. As illustrated, iPSCs have the ability to differentiate into all human cell types. Vita Therapeutics utilizes iPSCs to engineer specific cell types that are designed to replace those that are defective in patients. To deliver these cells we focus on two distinct methodologies: the autologous approach, a patient-specific therapy, and a hypoimmunogenic approach, a universal cell designed to be used for all patients.

To learn more about Vita Therapeutics, visit http://www.vitatx.com/

Contact:
Douglas Falk, Chief Executive Officer
609-339-5126
https://www.linkedin.com/in/douglas-falk-29653057/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved